ATE244304T1 - Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert - Google Patents

Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert

Info

Publication number: ATE244304T1
Authority: AT; Austria
Prior art keywords: receptor; hypothalamic; neuropeptide; atypical; peptide
Prior art date: 1994-12-02

Application number

AT95943642T

Other languages

English (en)

Inventor

Christophe P G Gerald

Mary W Walker

Theresa Branchek

Richard L Weinshank

Original Assignee

Synaptic Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-02

Filing date

1995-12-01

Publication date

2003-07-15

1995-12-01 Application filed by Synaptic Pharma Corp filed Critical Synaptic Pharma Corp

2003-07-15 Application granted granted Critical

2003-07-15 Publication of ATE244304T1 publication Critical patent/ATE244304T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
108050002826 Neuropeptide Y Receptor Proteins 0.000 title 1
102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
230000020595 eating behavior Effects 0.000 title 1
230000002267 hypothalamic effect Effects 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
108010070727 peptide YY receptor Proteins 0.000 title 1
101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
230000005856 abnormality Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000946 synaptic effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Microbiology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)

AT95943642T 1994-12-02 1995-12-01 Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert ATE244304T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/349,025 US5602024A (en)	1994-12-02	1994-12-02	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
PCT/US1995/015646 WO1996016542A1 (en)	1994-12-02	1995-12-01	Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)

Publications (1)

Publication Number	Publication Date
ATE244304T1 true ATE244304T1 (de)	2003-07-15

Family

ID=23370577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95943642T ATE244304T1 (de)	1994-12-02	1995-12-01	Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert

Country Status (12)

Country	Link
US (5)	US5602024A (de)
EP (2)	EP0732875B1 (de)
JP (2)	JPH10510709A (de)
AT (1)	ATE244304T1 (de)
AU (1)	AU713713C (de)
CA (1)	CA2174529C (de)
DE (2)	DE732875T1 (de)
DK (1)	DK0732875T3 (de)
ES (1)	ES2092976T3 (de)
GR (1)	GR960300058T1 (de)
PT (1)	PT732875E (de)
WO (1)	WO1996016542A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5516653A (en) *	1993-12-28	1996-05-14	Synaptic Pharmaceutical Corporation	DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) *	1994-02-03	1996-08-13	Synaptic Pharmaceutical Corporation	DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US6010861A (en) *	1994-08-03	2000-01-04	Dgi Biotechnologies, Llc	Target specific screens and their use for discovering small organic molecular pharmacophores
US5989920A (en) *	1994-12-02	1999-11-23	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) *	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
AUPN646795A0 (en) *	1995-11-09	1995-11-30	Garvan Institute Of Medical Research	Neuropeptide Y-Y5 receptor
AU772193B2 (en) *	1995-11-09	2004-04-08	Garvan Institute Of Medical Research	Neuropeptide Y-Y5 receptor
AU1328197A (en) *	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
US5965392A (en) *	1996-04-08	1999-10-12	Bayer Corporation	Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) *	1996-04-08	1999-07-06	Bayer Corporation	Neuropeptide Y receptor Y5 and nucleic acid sequences
WO1997046250A1 (en) *	1996-06-04	1997-12-11	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
EP0969852A4 (de) *	1996-10-31	2004-05-06	Merck & Co Inc	Kombinationstherapie zur behandlung von diabetes und fettsucht
US6048900A (en)	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6245817B1 (en)	1997-02-14	2001-06-12	Bayer Corporation	NPY5 receptor antagonists and methods for using same
WO1998035957A1 (en) *	1997-02-14	1998-08-20	Bayer Corporation	Amide derivatives as selective neuropeptide y receptor antagonists
US6713265B1 (en)	1997-06-04	2004-03-30	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5916869A (en) *	1997-06-13	1999-06-29	North Carolina State University	Method of treating birds in ovo
AU8474298A (en) *	1997-07-31	1999-02-22	Bristol-Myers Squibb Company	A method for modulation of circadian rhythmicity
PT896822E (pt) *	1997-08-05	2003-07-31	Pfizer Prod Inc	4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
US5985616A (en) *	1998-01-07	1999-11-16	Schering Corporation	Chimeric mammalian NPY Y5 receptors
US6197530B1 (en) *	1998-09-22	2001-03-06	Millennium Pharmaceuticals, Inc.	GPR10 as a target for identifying weight modulating compounds
EP1129089B1 (de)	1998-11-10	2005-12-28	Merck & Co., Inc.	Spiro-indole als y5-rezeptor antagonisten
US7745216B2 (en)	1999-02-10	2010-06-29	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
IL144703A (en)	1999-02-10	2010-04-15	Curis Inc	Use of peptide yy for the preparation of a pharmaceutical composition for enhancing pancreatic cell differentiation
US6407120B1 (en)	1999-02-18	2002-06-18	Pfizer Inc.	Neuropeptide Y antagonists
US6221660B1 (en)	1999-02-22	2001-04-24	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
US6713473B1 (en)	1999-04-20	2004-03-30	Meiji Seika Kaisha, Ltd.	Tricyclic compounds
EP1177188B1 (de)	1999-05-12	2005-10-12	Ortho-McNeil Pharmaceutical, Inc.	Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
US20050020547A1 (en) *	1999-11-08	2005-01-27	Pfizer Inc.	Compounds for the treatment of female sexual dysfunction
WO2001053477A1 (en) *	2000-01-20	2001-07-26	Baylor College Of Medicine	Methods and compositions for control of bone formation via modulation of neuropeptide y activity
WO2001055103A2 (en) *	2000-01-28	2001-08-02	Neurogen Corporation	Chimeric neuropeptide y receptors
GB0010757D0 (en)	2000-05-05	2000-06-28	Astrazeneca Ab	Chemical compounds
JP2004520299A (ja)	2000-12-12	2004-07-08	ニューロジェン・コーポレーション	スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
EP2123293A3 (de)	2000-12-14	2010-09-08	Amylin Pharmaceuticals, Inc.	Peptid YY und Peptid YY-Agonisten zur Behandlung von Stoffwechselstörungen
SG138463A1 (en)	2000-12-21	2008-01-28	Schering Corp	Heteroaryl urea neuropeptide y y5 receptor antagonists
WO2002051857A1 (en) *	2000-12-21	2002-07-04	Genaissance Pharmaceuticals, Inc.	Drug target isogenes: polymorphisms in the neuropeptide y gene
US6946476B2 (en)	2000-12-21	2005-09-20	Schering Corporation	Heteroaryl urea neuropeptide Y Y5 receptor antagonists
DE10125961A1 (de) *	2001-05-29	2002-12-12	Boehringer Ingelheim Int	Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
AU2002355286B2 (en)	2001-07-26	2005-10-13	Schering Corporation	Substituted urea neuropeptide Y Y5 receptor antagonists
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
GB0121941D0 (en)	2001-09-11	2001-10-31	Astrazeneca Ab	Chemical compounds
EP1585956A4 (de) *	2001-09-24	2009-10-21	Univ Oregon Health & Science	Beurteilung von neuronen im nucleus arcuatus zum screening auf das essverhalten verändernde stoffe
ES2320979T3 (es) *	2001-09-24	2009-06-01	Imperial Innovations Limited	Pyy-36 para la reduccion o prevencion de la obesidad.
CA2403307A1 (en) *	2001-10-23	2003-04-23	Neurogen Corporation	Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
US7877273B2 (en) *	2002-01-08	2011-01-25	Fredric David Abramson	System and method for evaluating and providing nutrigenomic data, information and advice
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US20060122106A1 (en) *	2002-06-14	2006-06-08	Amylin Pharmaceuticals, Inc	Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
EP1601666A2 (de)	2002-07-02	2005-12-07	Schering Corporation	Neuropeptid y y5 rezeptor antagonisten
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7811989B2 (en)	2003-01-17	2010-10-12	Ipsen Pharma S.A.S.	Peptide YY analogs
AU2003260187A1 (en) *	2003-09-18	2005-04-06	Garvan Institute Of Medical Research	Methods of modulating bone growth, bone remodeling and adiposity
EP1789440A4 (de) *	2004-02-11	2008-03-12	Amylin Pharmaceuticals Inc	Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide
US20070270339A1 (en) *	2004-04-23	2007-11-22	Serono, Inc.	Use of GPCR54 Ligands for the Treatment of Infertility
JP2008501035A (ja) *	2004-05-28	2008-01-17	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	妊孕性関連障害の治療におけるｉｌ−１７の使用
CA2610022A1 (en) *	2005-06-06	2006-12-14	Georgetown University	Compositions and methods for lipo modeling
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
WO2007125952A1 (ja)	2006-04-28	2007-11-08	Shionogi & Co., Ltd.	Ｎｐｙｙ５受容体拮抗作用を有するアミン誘導体
US8088777B2 (en)	2006-08-30	2012-01-03	Shionogi & Co., Ltd.	Urea derivative
US8344180B2 (en)	2006-08-30	2013-01-01	Shionogi & Co., Ltd.	Hydrazine amide derivative
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
WO2008137270A1 (en) *	2007-05-04	2008-11-13	H. Lundbeck A/S	Methods of diagnosing and monitoring of npy y5 based disorders
SA08290668B1 (ar)	2007-10-25	2012-02-12	شيونوجي آند كو.، ليمتد	مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
CL2009000904A1 (es)	2008-04-21	2010-04-30	Shionogi & Co	Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EP2404896A1 (de)	2009-03-05	2012-01-11	Shionogi&Co., Ltd.	Cyclohexanderivat mit npy-y5-rezeptorantagonismus
US8227618B2 (en)	2009-04-23	2012-07-24	Shionogi & Co., Ltd.	Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
KR101392942B1 (ko)	2010-12-10	2014-05-12	한국생명공학연구원	인간 신경 펩티드 수용체 형질전환 초파리를 이용한 비만 치료제 스크리닝 방법
CN111494606B (zh) *	2020-04-24	2021-12-14	广州医科大学	神经肽y的新应用
EP4366755A4 (de) *	2021-07-08	2025-09-24	Gila Therapeutics Inc	Zusammensetzungen und verfahren zur aktivierung eines neuronalen rezeptors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328899A (en)	1988-07-15	1994-07-12	The Salk Institute For Biological Studies	NPY peptide analogs
US5026685A (en)	1988-07-15	1991-06-25	The Salk Institute For Biological Studies	NPY peptide analogs
ZA896374B (en)	1988-08-26	1990-05-30	Merrell Dow Pharma	Neuropeptide y antagonists
ZA896376B (en)	1988-08-26	1990-05-30	Merrell Dow Pharma	Neuropeptide y agonists
EP0448765B1 (de) *	1990-03-30	1994-08-17	HEUMANN PHARMA GMBH & CO	Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung
SE9002278L (sv)	1990-06-28	1991-12-29	Perstorp Ab	Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
JP3419454B2 (ja) *	1991-11-06	2003-06-23	ガーヴァンインスティチュートオブメディカルリサーチ	ヒト神経ペプチドｙ−ｙ１レセプター
WO1993012139A1 (en)	1991-12-19	1993-06-24	Garvan Institute Of Medical Research	A novel molecule which inhibits neuropeptide tyrosine biological function
WO1993024515A1 (en) *	1992-05-29	1993-12-09	Cornell Research Foundation, Inc.	Human neuropeptide y/peptide yy receptor of the y1-type and antisense oligonucleotides thereto which inhibit vasoconstriction
GB9213215D0 (en)	1992-06-20	1992-08-05	Wellcome Found	Peptides
JPH06116284A (ja)	1992-10-02	1994-04-26	Yamanouchi Pharmaceut Co Ltd	新規ペプチド
FR2701480B1 (fr)	1993-02-15	1995-05-24	Sanofi Elf	Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CN1124927A (zh)	1993-03-29	1996-06-19	辛辛那提大学	Yy肽类似物及其应用
JPH11501281A (ja)	1993-06-18	1999-02-02	ユニバーシティオブシンシナティ	神経ペプチドｙアンタゴニスト及びアゴニスト
IL110298A (en) *	1993-07-13	1999-04-11	Brann Mark Robert	Identification of ligands by selective amplification of cells transfected with receptors
US5516653A (en) *	1993-12-28	1996-05-14	Synaptic Pharmaceutical Corporation	DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) *	1994-02-03	1996-08-13	Synaptic Pharmaceutical Corporation	DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US6114139A (en) *	1994-08-11	2000-09-05	Takeda Chemical Industries, Ltd.	G-protein coupled receptor protein and a DNA encoding the receptor
WO1996012489A1 (en)	1994-10-20	1996-05-02	Eli Lilly And Company	Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en)	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
CA2134428A1 (en)	1994-10-26	1996-04-27	Albert Tseng	Neuropeptide y y2 agonist peptides
WO1996014307A1 (en)	1994-11-07	1996-05-17	Pfizer Inc.	Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
JPH10508486A (ja) *	1994-11-07	1998-08-25	メルクエンドカンパニーインコーポレーテッド	修飾神経ペプチドｙレセプター
US5602024A (en) *	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en)	1994-12-02	1999-11-23	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5621079A (en) *	1995-02-03	1997-04-15	Merck & Co., Inc.	Neuropeptide Y receptor
US5554621A (en)	1995-06-07	1996-09-10	Bristol-Myers Squibb Company	Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
AUPN646795A0 (en) *	1995-11-09	1995-11-30	Garvan Institute Of Medical Research	Neuropeptide Y-Y5 receptor
WO1997020822A1 (en)	1995-12-01	1997-06-12	Novartis Ag	Quinazolin-2,4-diazirines as npy receptor antagonist
AU7626496A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Heteroaryl compounds
US5965392A (en)	1996-04-08	1999-10-12	Bayer Corporation	Neuropeptide Y receptor Y5 and nucleic acid sequences
WO1997046250A1 (en)	1996-06-04	1997-12-11	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
US6713265B1 (en) *	1997-06-04	2004-03-30	Synaptic Pharmaceutical Corporation	Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

1994
- 1994-12-02 US US08/349,025 patent/US5602024A/en not_active Expired - Lifetime
1995
- 1995-12-01 DE DE0732875T patent/DE732875T1/de active Pending
- 1995-12-01 EP EP95943642A patent/EP0732875B1/de not_active Expired - Lifetime
- 1995-12-01 DE DE69531190T patent/DE69531190T2/de not_active Expired - Lifetime
- 1995-12-01 DK DK95943642T patent/DK0732875T3/da active
- 1995-12-01 CA CA002174529A patent/CA2174529C/en not_active Expired - Lifetime
- 1995-12-01 AU AU45063/96A patent/AU713713C/en not_active Expired
- 1995-12-01 JP JP8519094A patent/JPH10510709A/ja active Pending
- 1995-12-01 WO PCT/US1995/015646 patent/WO1996016542A1/en not_active Ceased
- 1995-12-01 ES ES95943642T patent/ES2092976T3/es not_active Expired - Lifetime
- 1995-12-01 US US08/566,096 patent/US5968819A/en not_active Expired - Lifetime
- 1995-12-01 EP EP03009825A patent/EP1382616A3/de not_active Withdrawn
- 1995-12-01 AT AT95943642T patent/ATE244304T1/de active
- 1995-12-01 PT PT95943642T patent/PT732875E/pt unknown
1996
- 1996-11-30 GR GR960300058T patent/GR960300058T1/el unknown
1998
- 1998-11-25 US US09/200,673 patent/US6316203B1/en not_active Expired - Lifetime
2001
- 2001-09-24 US US09/962,646 patent/US6818445B2/en not_active Expired - Fee Related
2003
- 2003-10-15 JP JP2003355108A patent/JP2004137276A/ja not_active Withdrawn
2004
- 2004-11-12 US US10/987,856 patent/US20060014242A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US5602024A (en)	1997-02-11
US6818445B2 (en)	2004-11-16
US20060014242A1 (en)	2006-01-19
AU713713B2 (en)	1999-12-09
WO1996016542A1 (en)	1996-06-06
JP2004137276A (ja)	2004-05-13
US6316203B1 (en)	2001-11-13
DE732875T1 (de)	1997-01-30
CA2174529C (en)	2003-02-11
EP0732875A4 (de)	1997-02-26
JPH10510709A (ja)	1998-10-20
DK0732875T3 (da)	2003-10-27
PT732875E (pt)	2003-11-28
AU4506396A (en)	1996-06-19
EP0732875A1 (de)	1996-09-25
ES2092976T1 (es)	1996-12-16
AU713713C (en)	2004-04-08
US5968819A (en)	1999-10-19
EP1382616A3 (de)	2004-01-28
ES2092976T3 (es)	2004-05-01
US20020103123A1 (en)	2002-08-01
GR960300058T1 (en)	1996-11-30
DE69531190D1 (de)	2003-08-07
DE69531190T2 (de)	2004-04-15
CA2174529A1 (en)	1996-06-03
EP1382616A2 (de)	2004-01-21
EP0732875B1 (de)	2003-07-02

Legal Events

Date

Code

Title

Description

2004-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0732875

Country of ref document: EP

2006-01-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
DE69531190D1 (de)	2003-08-07	Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert
DE60121808D1 (de)	2006-09-07	Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
EE200000318A (et)	2001-08-15	Uudsed ühendid
MXPA02011656A (es)	2004-07-30	Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE518532T1 (de)	2011-08-15	Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz
MX9704030A (es)	1998-02-28	1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
NO972391L (no)	1997-05-26	2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DE69839566D1 (de)	2008-07-10	Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
DE69530844D1 (de)	2003-06-26	Verfahren und substanzen gegen protozoen
EE200100472A (et)	2002-12-16	Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
ATE311476T1 (de)	2005-12-15	Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
EP0537981A3 (de)	1994-10-12	Verfahren zur Spaltung von Acylthiohydantoinen und Anwendung davon zur C-terminalen Peptidsequenzierung.
DE69940793D1 (de)	2009-06-04	Chimärisches Gen, dass für die antigenischen Determinanten von vier Proteinen aus L. Infantum kodiert
ATE225171T1 (de)	2002-10-15	Aminosäurederivate zur behandlung von schlaganfall
DE69009196D1 (de)	1994-07-07	EEPROM, dessen Löschgate-Elektrodenmuster, die Muster des Source-Bereiches kreuzen und Verfahren zur Herstellung desselben.
ATE190630T1 (de)	2000-04-15	Angiotensin-ii typ-1 rezeptor und dessen herstellung
ATE225805T1 (de)	2002-10-15	Hundecoronavirus s gen und verwendung davon
ATE330011T1 (de)	2006-07-15	Bevorzugte segmente des ntp-proteins (neural thread protein) und verfahren zu deren verwendung
EP0645454A3 (de)	1997-01-15	Chimäres Somatostatin enthaltendes Protein und kodierende DNA, Immunogen-Zusammensetzungen und Verfahren zur Erhöhung des Produktions von Farmtieren.
ID23184A (id)	2000-03-23	Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE59410423D1 (de)	2006-01-12	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69930545D1 (de)	2006-05-11	Verfahren zur diagnose und behandlung neurologischer erkrankungen
DE60043106D1 (de)	2009-11-19	Polypeptide und deren dna
DE60234843D1 (de)	2010-02-04	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE3777359D1 (de)	1992-04-16	Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.